fingolimod hydrochloride has been researched along with osu-2s in 4 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (osu-2s) | Trials (osu-2s) | Recent Studies (post-2010) (osu-2s) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 7 | 0 | 7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berman-Booty, LD; Byrd, JC; Chen, CS; Chou, CC; Hung, JH; Kogure, T; Kulp, SK; Ma, Y; Muthusamy, N; Omar, HA; Patel, T; Terracciano, L; Wang, D | 1 |
| Byrd, JC; Chen, CS; Lee, LJ; Lee, RJ; Li, H; Mao, Y; Muthusamy, N; Phelps, MA; Wang, J; Yan, R; Zhao, Y | 1 |
| Baiocchi, R; Baskar, S; Byrd, JC; Chen, CS; Chiang, CL; Frissora, FW; Klisovic, R; Lee, LJ; Lee, RJ; Mani, R; Mo, X; Muthusamy, N; Phelps, MA; Rader, C; Yan, R | 1 |
| Bennett, C; Byrd, JC; Chen, M; Coss, CC; Cui, F; Freed, C; Goswami, S; Jennings, RN; Kisseberth, WC; Kulp, SK; Lewis, S; Malbrue, R; Mani, R; Muthusamy, N; Phelps, MA; Schaaf, LJ; Schober, KK; Wang, D; Xie, Z | 1 |
4 other study(ies) available for fingolimod hydrochloride and osu-2s
| Article | Year |
|---|---|
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Fingolimod Hydrochloride; Hepatocytes; Humans; Liver Neoplasms; Mice; Mice, Nude; Propylene Glycols; Protein Kinase C-delta; Reactive Oxygen Species; Signal Transduction; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.
Topics: Animals; Chromatography, Liquid; Female; Fingolimod Hydrochloride; Half-Life; Mice; Mice, Inbred ICR; Plasma; Propylene Glycols; Sphingosine; Tandem Mass Spectrometry | 2014 |
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Cytotoxins; Drug Delivery Systems; Fingolimod Hydrochloride; Histocompatibility Antigens Class II; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Propylene Glycols; Receptor Tyrosine Kinase-like Orphan Receptors; Sphingosine; Xenograft Model Antitumor Assays | 2015 |
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.
Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Data Analysis; Dogs; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Haplorhini; Humans; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Rats; Rats, Sprague-Dawley; Sphingosine | 2020 |